Segui
Timothy Hickling
Timothy Hickling
Immunosafety Lead, Roche
Email verificata su roche.com
Titolo
Citata da
Citata da
Anno
Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding
AM Owsianka, JM Timms, AW Tarr, RJP Brown, TP Hickling, A Szwejk, ...
Journal of virology 80 (17), 8695-8704, 2006
3142006
Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33
AW Tarr, AM Owsianka, JM Timms, PC McClure, RJP Brown, TP Hickling, ...
Hepatology 43 (3), 592-601, 2006
2142006
A recombinant trimeric surfactant protein D carbohydrate recognition domain inhibits respiratory syncytial virus infection in vitro and in vivo
TP Hickling, H Bright, K Wing, D Gower, SL Martin, RB Sim, R Malhotra
European journal of immunology 29 (11), 3478-3484, 1999
1751999
Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics
J Davda, P Declerck, S Hu-Lieskovan, TP Hickling, IA Jacobs, J Chou, ...
Journal for immunotherapy of cancer 7, 1-9, 2019
1192019
Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domain
MR Müller, K Saunders, C Grace, M Jin, N Piche-Nicholas, J Steven, ...
MAbs 4 (6), 673-685, 2012
1042012
Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33
AW Tarr, AM Owsianka, D Jayaraj, RJP Brown, TP Hickling, WL Irving, ...
Journal of General Virology 88 (11), 2991-3001, 2007
1002007
Mannan binding lectin and viral hepatitis
KS Brown, SD Ryder, WL Irving, RB Sim, TP Hickling
Immunology letters 108 (1), 34-44, 2007
912007
Lung surfactant protein A provides a route of entry for respiratory syncytial virus into host cells
TP HICKLING, R MALHOTRA, H BRIGHT, W MCDOWELL, ED BLAIR, ...
Viral immunology 13 (1), 125-135, 2000
892000
Therapeutic outcomes, assessments, risk factors and mitigation efforts of immunogenicity of therapeutic protein products
L Yin, X Chen, P Vicini, B Rup, TP Hickling
Cellular Immunology 295 (2), 118-126, 2015
862015
The development of a fully-integrated immune response model (FIRM) simulator of the immune response through integration of multiple subset models
S Palsson, TP Hickling, EL Bradshaw-Pierce, M Zager, K Jooss, ...
BMC systems biology 7, 1-19, 2013
762013
Collectins and their role in lung immunity
TP Hickling, H Clark, R Malhotra, RB Sim
Journal of Leucocyte Biology 75 (1), 27-33, 2004
752004
Human lung surfactant protein A exists in several different oligomeric states: oligomer size distribution varies between patient groups
TP Hickling, R Malhotra, RB Sim
Molecular Medicine 4, 266-275, 1998
751998
Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab
B Gorovits, DJ Baltrukonis, I Bhattacharya, MA Birchler, D Finco, ...
Clinical & Experimental Immunology 192 (3), 348-365, 2018
702018
A mechanistic, multiscale mathematical model of immunogenicity for therapeutic proteins: part 1—theoretical model
X Chen, TP Hickling, P Vicini
CPT: pharmacometrics & systems pharmacology 3 (9), 1-9, 2014
642014
Specific interaction of hepatitis C virus glycoproteins with mannan binding lectin inhibits virus entry
KS Brown, MJ Keogh, AM Owsianka, R Adair, AH Patel, JN Arnold, ...
Protein & cell 1, 664-674, 2010
632010
Severe fibrosis in hepatitis C virus-infected patients is associated with increased activity of the mannan-binding lectin (MBL)/MBL-associated serine protease 1 (MASP-1) complex
KS Brown, MJ Keogh, N Tagiuri, MJ Grainge, JS Presanis, SD Ryder, ...
Clinical & Experimental Immunology 147 (1), 90-98, 2007
612007
Contribution of enhanced engagement of antigen presentation machinery to the clinical immunogenicity of a human interleukin (IL)-21 receptor-blocking therapeutic antibody
L Xue, T Hickling, R Song, J Nowak, B Rup
Clinical & Experimental Immunology 183 (1), 102-113, 2016
512016
Immunogenicity of biosimilars for rheumatic diseases, plaque psoriasis, and inflammatory bowel disease: a review from clinical trials and regulatory documents
V Strand, J Gonçalves, TP Hickling, HE Jones, L Marshall, JD Isaacs
BioDrugs 34, 27-37, 2020
502020
A mathematical model of the effect of immunogenicity on therapeutic protein pharmacokinetics
X Chen, T Hickling, E Kraynov, B Kuang, C Parng, P Vicini
The AAPS journal 15, 1141-1154, 2013
452013
Induction of TNF-α release from human buffy coat cells by Pseudomonas aeruginosa is reduced by lung surfactant protein A
TP Hickling, RB Sim, R Malhotra
FEBS letters 437 (1-2), 65-69, 1998
451998
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20